


Accepted Manuscript

Title: Monocyte and interferon based therapy for the treatment of ovarian cancer

Author: Daniel S. Green Ana T. Nunes Christina M. Annunziata Kathryn C. Zoon



PII: S1359-6101(16)30030-2
DOI: <http://dx.doi.org/doi:10.1016/j.cytogfr.2016.02.006>
Reference: CGFR 921

To appear in: *Cytokine & Growth Factor Reviews*

Received date: 16-2-2016
Accepted date: 27-2-2016

Please cite this article as: {<http://dx.doi.org/>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title: Monocyte and interferon based therapy for the treatment of ovarian cancer.

Daniel S. Green^{1*}, Ana T. Nunes², Christina M. Annunziata², Kathryn C. Zoon¹

¹Cytokine Biology Section, National Institute of Allergy and Infectious Diseases, National Institute of Health

²Translational Genomics Section, National Cancer Institute, National Institutes of Health

Address Correspondence to: *Daniel S. Green (Daniel.green2@nih.gov), Cytokine Biology Section, NIAID, NIH, 50 South Drive, RM 5515, Bethesda MD USA, 20892

Ana T. Nunes (ana.nunes@nih.gov), Medical Oncology Branch, NCI, 10 Center DR, RM 12N226, Bethesda MD USA, 20814

Christina M. Annunziata (ca180n@nih.gov), Women's Malignancy Branch, NCI, NIH, Translational Genomics Section, 10 Center DR RM 3B43A, Bethesda MD USA, 20892

Kathryn C. Zoon (kz15m@nih.gov), Cytokine Biology Section, NIAID, NIH, 50 South Drive, RM 5515, Bethesda MD USA, 20892

Highlights

1. Introduction
2. Interferons and the treatment of cancer
3. Monocytes and Macrophages
4. Combination therapies and the future

Abstract:

Cytokines and cells of the innate immune system have been shown to be critical regulators in the elimination, equilibrium and escape of malignant cells. Despite *in vitro* and *in vivo* evidence, components of the innate immune system have shown limited efficacy in the treatment of ovarian cancer. Intraperitoneal immunotherapies are a promising field that has not yet been fully explored in ovarian cancer. Cytokine immunotherapy using interferon alpha (IFN- α) and interferon gamma (IFN- γ) has predominantly been used intraperitoneally in ovarian cancer, with promising results. Early studies also showed that autologous monocytes infused into the peritoneum have anti-tumor properties. Combination therapies have been shown to be more effective in treating cancer than monotherapies. Based on these observations the combination of cell therapy with cytokine therapy may provide a unique strategy for the treatment of chemotherapy resistant solid cancers.

Key Words: Monocyte, Interferon Alpha, Interferon Gamma, Ovarian Cancer, immunotherapy.

Download English Version:

<https://daneshyari.com/en/article/8466543>

Download Persian Version:

<https://daneshyari.com/article/8466543>

[Daneshyari.com](https://daneshyari.com)